BioPharma

dna-sequencing-banner
0

Is Amgen The Next Big Split?

First Abbott split and created AbbVie, then Baxter with Baxalta, is Amgen up next? I am placing best the new spin off will be called Pmgen. Hedge fund manager Daniel Loeb is lending his voice to the chorus of investors who believe Amgen ($AMGN) would do better as two companies. And his firm, Third Point,…

wpid-Photo-20140711095706.jpg
0

FDA Extends Exclusivity for Certain Combo-Meds

What’s two extra years of exclusivity worth? Enough to spark a legal fight. The FDA posted new guidance on its website Friday, awarding certain combo meds 5 years of exclusivity compared with the previous three. Drugmakers had lobbied for the change, but the timing–and the wording–are bound to be controversial.

man woman hands holding broken heart
0

Are Shire and AbbVie on the Outs?

Following Shire plc’s (“Shire”) waiver of the three-day notice period, AbbVie Inc. (“AbbVie”) (NYSE: ABBV) announces today its Board of Directors’ withdraws its recommendation made on July 18, 2014 regarding the proposed Shire transaction and recommends that stockholders vote against the transaction.

venture-capital-feature-2wdk2kfp0bd1nyo8j9y4g0
0

GSK Announces $5M Innovation Challenge Fund for Bioelectronic Medicine

GSK announced a $5 million Innovation Challenge Fund (ICF) to further encourage and advance collaborative research as part of its effort to develop bioelectronic medicines. The fund will support academic groups and small companies who want to develop solutions for GSK’s Bioelectronics Innovation Challenge, which was developed by a group of leading scientists from around…

Copyright © 2014 WhiteCityNews, All rights reserved.